ADVANCED SOLID TUMORS

This early-phase study tested a new drug (PF-07265028) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head/neck cancers. The goal was to find the safest dose and see if the drug shrinks tumors. The study was stopped early, and…

This early-phase study tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety and find the right dose. The drug works by helping …

This study tested a new drug called ASP2074 in 23 adults with advanced solid tumors that had spread or couldn't be removed. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.

This early-phase trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was ended early, so res…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and find the best dose. The study was terminated early, so results are limited.

This early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The st…

This early-stage study tested an experimental drug called VVD-130850 in people with advanced solid tumors or blood cancers. The drug works by blocking a protein (STAT3) that helps cancers grow. Some participants also received a second drug to boost the immune system. The main goa…

This early-phase study tested a new drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limit…

This early-phase study tested a new treatment called HV-101 for people with advanced solid tumors that had come back or spread. The treatment uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back to fight the cancer. The study was st…

This early-phase study tested a new drug called BGB-30813, alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs could shri…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 adults with advanced solid tumors that had come back or worsened after prior platinum-based treatment. The main goals were to find the safest dose and check for side effe…

This early-stage study tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, and it does not aim to c…

This early-phase study tested a new drug called INCB081776, alone or with another drug, in 83 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated early, so result…

This early-stage study tested an experimental oral drug called ATX-559 in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. The study was terminated early, so results are lim…

This early-phase study tested a new drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors like head and neck or gastrointestinal cancers. The goal was to check safety and find the right dose. The study was terminated early, so result…